The Morning Read provides a 24-hour wrap up of everything else healthcare’s innovators need to know about the business of medicine (and beyond). The author of The Read published it but all full-time MedCity News journalists contribute to its content.
TOP STORIES
Stop checking your mainstream media sites, deactivate your “Obamacare” alerts and throw out the front sections of this week’s newspapers: It’s the fifth anniversary of the Affordable Care Act. The stories will likely be endless. Coverage started with a resounding oy vey with Obama telling the ACA’s critics to embrace reality (#nothappening). The Associated Press, meanwhile, gives a nice then-and-now look at life before Obamacare and now, while Forbes points out employers have warmed to the ACA.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Is Bob Wachter’s book going to be hotter than Eric Topol’s? Here’s Wachter’s New York Times piece, “Why health care tech is still so bad” and some immediate reaction: “I love the idea of EHRs, but I hate how it is being done.”
Biogen Idec has changed its name to Biogen. CEO George Scangos on the company’s strategy: “Not all of it is going to work, and some of it will.” Eh?
LIFE SCIENCE
A great deep dive on the chance of gene therapy curing hemophilia.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Is big pharma really scared of Google and Apple? They’re already collaborating.
Moving on from a biotech tragedy: the 2013 shootings by biotech executive Hans Petersen.
PAYERS-PROVIDERS
Healthcare’s innovators should join Tuesday’s discussion on depression, startups and entrepreneurs. The hashtag is #startupdepression.
We’re one year into Ebola. A report states that a slow international response cost thousands of lives. But they outbreak could also all be over by August.
Seriously, why does KevinMD keep running this awful post about patients not being customers? It was awful the first time.
Analysis of the viral photo of the weeping ER doctor: “If you don’t cry, you die.”
Match Day: The biggest yet.
11 medical students may have traveled to work in ISIS hospitals
TECH
Ex-New York Mayor Michael Bloomberg goes all-in on health data with a $100 million project with the Australian government
POLITICS
We shouldn’t have gotten excited about the Doc Fix. The politicians are still negotiating.
Big tobacco: the health advocate (when it comes to e-cigarettes)
Obamacare may be helping most in the treatment of diabetics.
Would issuing a stay in the King v. Burwell case be a good thing? (No.)
Kansas finally getting behind a bigger Medicaid?
A LITTLE EXTRA
I defy you to find the person who volunteers to try this first: Expect 3D printed eyes by 2027, providing enhanced vision & wifi connection
[Photo of a medical device from the Brockhaus and Efron Encyclopedic Dictionary published in Russia (1890-1907) is from Flickr user Double-M]
